Tempus AI (TEM) Q1 2026 Earnings Transcript

Tempus AI reported Q1 revenue of $348.1 million, up more than 36% year over year, with diagnostics revenue rising to $261.1 million and data applications revenue up 40.5% to $87 million. Management raised full-year revenue guidance to $1.59 billion-$1.60 billion and adjusted EBITDA guidance to about $65 million, while highlighting major new pharma collaborations with Merck and an expanded Gilead relationship. The call also emphasized strong TCV visibility, continued algorithm attach-rate gains, and pending FDA/regulatory milestones that could support further ASP expansion.

Analysis

Tempus is transitioning from a “promising AI diagnostics story” to a real recurring-revenue platform with two reinforcing engines: higher diagnostic ASPs and a deepening data-annuity. The underappreciated second-order effect is that each new pharma relationship not only adds revenue, it also increases the defensibility of the dataset itself because model-building workflows create switching costs far beyond simple data licensing. That should tighten the valuation gap versus slower-growing healthcare IT names, but it also means the market may still be underestimating how much of 2027+ is already visibility-backed rather than purely aspirational.

The most interesting read-through is to the competitive set. For PSNL, the MRD signal is a warning that Tempus can choose to throttle volume until reimbursement improves, which protects margin but also means category growth may be more supply-constrained than demand-constrained. For the broader oncology workflow, the company is effectively monetizing clinical decision support before it monetizes pure test volume, which favors platforms with embedded data loops over point-solution assay vendors. That also raises the bar for smaller diagnostics players that lack a monetizable data layer and may have to compete on price or niche indications.

The biggest risk is not demand; it is execution on regulatory and reimbursement timing. If FDA/ADLT milestones slip by one or two quarters, the market will likely compress the stock because the current bull case leans heavily on multiple simultaneous catalysts rather than one durable inflection. Cash burn on MRD is a real governor: if the company accelerates volumes too quickly before reimbursement broadens, margins can deteriorate faster than consensus expects. The contrarian view is that the setup may be less about near-term EPS and more about the probability that Tempus becomes a preferred AI infrastructure layer for biopharma R&D, which could justify a premium if backlog keeps compounding.

In the next 3-6 months, the key question is whether guidance proves conservative enough to drive a second re-rating after Investor Day, or whether the stock has already priced in too much of the 2026-27 TCV runway. The path to upside is straightforward: continued bookings above $100M, no regulatory delays, and sequential EBITDA expansion through the back half as data revenue converts. The path to downside is also clear: any disappointment in FDA timing or cash conversion will expose how dependent the story remains on multiple moving parts arriving on schedule.

Key Decisions for Investors

• Long TEM on pullbacks over the next 2-6 weeks; best risk/reward is entry on any post-call consolidation, with a 3-6 month target tied to Investor Day and updated FY26/FY27 visibility.
• Use TEM Jan-2027 call spreads rather than outright stock if liquidity permits; the thesis is backlog/TCV compounding plus margin expansion, while capping downside if FDA timing slips by a quarter or two.
• Pair long TEM / short PSNL for 3-9 months: Tempus has the stronger data monetization layer and pricing power, while PSNL is more exposed to reimbursement-dependent MRD adoption and a less durable moat.
• For event-driven traders, watch the pending XT/XF regulatory decisions as a catalyst window over the next 30-90 days; buy strength only after confirmation, since the stock is vulnerable to a “sell the news” reaction if approvals arrive without guide raises.
• If TEM rallies sharply into Investor Day without new TCV disclosure, consider trimming 20-30% and reloading on any post-event volatility; the market may front-run 2027 visibility too aggressively.